The role of anti-tumor necrosis factor receptor agents in cancer survivors revisited.
McClay
Edward F
EF
Institute for Melanoma Research & Education, Encinitas, CA, USA.
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009369:Neoplasms / Q000276:immunology; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000503:physiopathology*; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors*; D017741:Survivors
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor